Guidelines for the Use of Conventional and Newer Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis

Author： Díaz-Borjón Alejandro

Publisher： Adis International

ISSN： 1170-229X

Source： Drugs & Aging, Vol.26, Iss.4, 2009-05, pp. : 273-293

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine

By Umićević Mirkov Maša Coenen Marieke JH

Pharmacogenomics, Vol. 14, Iss. 4, 2013-03 ,pp. : 425-444

Future Medicine

Access to resources Recommend Favorite

Efficacy, Tolerability and Cost Effectiveness of Disease-Modifying Antirheumatic Drugs and Biologic Agents in Rheumatoid Arthritis

By Nurmohamed Michael T. Dijkmans Ben A.C.

Drugs, Vol. 65, Iss. 5, 2005-01 ,pp. : 661-694

Adis International

Access to resources Recommend Favorite

The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs

By Drozdzik Marek Rudas Tomasz Pawlik Andrzej Kurzawski Mateusz Czerny Bogusław Gornik Wanda Herczynska Magdalena

European Journal of Clinical Pharmacology, Vol. 62, Iss. 11, 2006-11 ,pp. : 933-937

Springer Publishing Company

Access to resources Recommend Favorite

Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis

By Fleischmann Roy

Expert Opinion on Drug Safety, Vol. 2, Iss. 4, 2003-07 ,pp. : 347-365

Informa Healthcare

Access to resources Recommend Favorite

A Clinical and Economic Review of Disease-Modifying Antirheumatic Drugs

By Gabriel S.E.

PharmacoEconomics, Vol. 19, Iss. 7, 2001-07 ,pp. : 715-728

Adis International

Access to resources Recommend Favorite